0
Inquiry Basket

There is no product in the shopping cart, buy it!

Anti-Tumor-associated Glycoprotein Antibody Development Services

Overview

Tumor-associated glycoproteins are widely overexpressed in cancers such as colorectal, ovarian, gastric, and breast, but are largely absent in normal adult tissues. Clinically relevant examples include LYPD3 and MUC family proteins, both linked to aggressive tumor progression. Early antibody efforts highlighted promise but faced issues of immunogenicity and specificity. Modern engineering—humanized formats, nanobodies, and bispecifics—has greatly enhanced stability, selectivity, and clinical potential, making antibody development against these glycoproteins a valuable path for diagnostics and targeted therapies.

Tailored antibody development solutions at Creative Biolabs help you accelerate cancer research and therapeutic discovery by delivering high-affinity, humanized antibodies against tumor-associated glycoproteins through advanced engineering platforms and optimized workflows. We employ strategic approaches to anti-tumor glycoprotein antibody development, combining antigen analysis, humanization, fragment optimization, novel modalities, bispecific engineering, and rigorous preclinical evaluation to ensure high specificity, stability, and therapeutic potential.

  • Comprehensive antigen analysis focusing on glycoepitopes such as sialyl-Tn
  • Humanization approaches to minimize immunogenicity and improve therapeutic potential
  • Antibody fragment optimization (scFv, Fab, VHH) for improved tumor penetration
  • Application of novel modalities, including immunocytokines and click-cleavable ADCs
  • Engineering bispecifics and multivalent antibodies for enhanced efficacy
  • Preclinical evaluation strategies that account for shedding and antigen heterogeneity

Accelerate Innovation with Creative Biolabs – Start Your Consultation Today

What We Can Offer

Antibody Discovery

Discovery services through hybridoma, phage, and yeast display platforms generate diverse, high-affinity candidates against tumor-associated glycoproteins.

Advanced Engineering

Humanization, affinity maturation, and Fc optimization reduce immunogenicity and improve therapeutic potential, ensuring antibodies are effective and manufacturable.

Developability Assessment

Evaluation of stability, solubility, and aggregation resistance identifies liabilities early, streamlining advancement of only the most robust candidates.

Diagnostic Solutions

Antibodies tailored for imaging and biomarker assays provide reliable detection in applications such as immunohistochemistry and ELISA.

Therapeutic Development

Antibody generation suitable for ADCs, bispecifics, and immunotherapies delivers versatile options for translational research and preclinical studies.

Comprehensive Reporting

Full characterization reports include binding data, specificity profiles, and clear recommendations to guide project decisions.

Service Portfolio

Anti-LYPD3 Antibody Development

Our service provides specialized Anti-LYPD3 antibodies for cancer research. These tools are designed for the precise detection of LYPD3, a key tumor marker, and are ideal for applications like IHC and Western blotting.

Anti-MUC Antibody Development

We offer custom Anti-MUC antibody development to study mucin proteins, which are often overexpressed in cancer. Our antibodies are subtype-specific, allowing for detailed analysis of MUCs as both diagnostic markers and potential therapeutic targets.

Workflow

01Target Analysis

Comprehensive review of tumor-associated glycoprotein expression profiles and epitope accessibility across cancer types.

02Antibody Generation

Application of hybridoma, phage, or yeast display technologies to yield diverse candidate panels.

03Humanization & Engineering

Framework grafting, affinity maturation, and Fc engineering to enhance therapeutic suitability.

04Developability Assessment

Evaluation of stability, solubility, aggregation resistance, and glycosylation profiles.

05Functional Validation

Binding kinetics, cellular assays, and in vivo biodistribution in xenograft models.

06Candidate Selection & Delivery

Delivery of lead antibodies with complete characterization reports and recommended next steps.

Required Starting Materials

  • Tumor tissue or cell line data demonstrating glycoprotein expression profiles
  • Client’s preferred antibody format requirements (e.g., IgG1, scFv, bispecific)
  • Target application context (therapeutic candidate, imaging reagent, or diagnostic assay)

Highlights


Diverse Platforms
Broad technology platforms spanning hybridoma, display libraries, and nanobody discovery

Dual Applications
Capability to generate both therapeutic-grade and diagnostic antibodies

Flexible Collaboration
Flexible engagement models from single modules to full-service pipelines

Discover the Creative Biolabs Advantage – Request Your Quote Now

Publication

A fully humanized anti-TAG-72-IL-2 fusion protein was evaluated as a single-agent therapy in a murine colon carcinoma model. Administration of the fusion construct resulted in significant tumor growth inhibition compared with control groups, highlighting its capacity to deliver targeted immune activation directly within the tumor microenvironment. Enhanced infiltration of CD8+ T cells and increased IFN-γ production were observed, correlating with reduced tumor burden and prolonged survival. These findings demonstrate that combining tumor-specific recognition with cytokine delivery can produce potent antitumor effects, supporting the potential of this fusion protein as a novel therapeutic approach for solid tumors.

Fig.1 Treatment of murine colon carcinoma using an IL-2 fusion protein targeting TAG-72 as a single-agent therapy. (OA Literature) Fig.1 Monotherapy with an anti-TAG-72–IL-2 fusion protein in a murine colon carcinoma model.1

Customer Reviews

Reliable Antibody Leads
Using Creative Biolabs' anti-tumor-associated glycoprotein antibody development services in our colorectal cancer project has significantly improved target specificity and reduced cross-reactivity.” Research Scientist, Dr. Joh***

Enhanced Stability
The engineered antibodies we received demonstrated superior solubility and aggregation resistance, which streamlined downstream formulation work.” Immuno-Oncology Group Lead, Dr. Mei***

Diagnostic Applications
Leveraging Creative Biolabs' expertise, we successfully developed a sensitive companion diagnostic assay for ovarian cancer, reducing false negatives in our clinical study.” Translational Researcher, Dr. And***

FAQs

Can you help reduce the immunogenicity of murine-derived antibodies?

Yes, our humanization and framework engineering significantly minimize immunogenicity while retaining affinity.

How do you address glycan heterogeneity in tumor samples?

We design strategies around conserved glycoepitopes like sialyl-Tn and use multiple antibody formats to ensure robust coverage.

Are nanobody formats available for this service?

Yes, we provide VHH-based nanobody development, which offers advantages in tumor penetration and novel diagnostic modalities.

Extended Services

Therapeutic Glycoprotein Development Services

We provide end-to-end solutions for designing and engineering therapeutic glycoproteins with enhanced stability, functionality, and manufacturability. Our expertise supports applications from early discovery through preclinical validation, ensuring candidates are optimized for translational success.

Glycoprotein Analysis Services

We offer comprehensive analytical platforms to characterize glycoprotein structure, glycosylation patterns, and functional activity. These services enable precise evaluation of quality attributes critical for drug development, diagnostics, and biomarker research.

Creative Biolabs’ anti-tumor-associated glycoprotein antibody development services combine scientific rigor with cutting-edge platforms to deliver solutions that advance oncology research and therapeutic innovation. Contact our team for more information and to discuss your project.

Reference

  1. Aniogo, Eric et al. “Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors.” Cancers vol. 17,9 1453. 26 Apr. 2025. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers17091453
For Research Use Only.

Related Services

Online Inquiry
Creative Biolabs-Glycoprotein Contact Us Follow us on
  • ()
    ()
    ()
ISO 9001 Certified - Creative Biolabs Quality Management System.
Close
Thanksgiving
Thanksgiving